[2,4-dimethoxy-6-(methoxymethyl)phenyl]boronic acid | 685886-70-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2,4-dimethoxy-6-(methoxymethyl)phenyl]boronic acid
• 英文别名: 2,4-dimethoxy-6-(methoxymethyl)phenylboric acid
• CAS: 685886-70-8
• 化学式: C₁₀H₁₅BO₅
• 分子量: 226.037
• InChiKey: LGOYYTNSVPIQIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.47
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  68.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [2,4-dimethoxy-6-(methoxymethyl)phenyl]boronic acid 、 7-bromo-N-(cyclopropylmethyl)-2-ethyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]pyrazolo[1,5-a]pyridin-3-amine 在 四(三苯基膦)钯 、 barium hydroxide octahydrate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 4.0h， 以50%的产率得到N-(cyclopropylmethyl)-7-[2,4-dimethoxy-6-(methoxymethyl)phenyl]-2-ethyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]pyrazolo[1,5-a]pyridin-3-amine
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of Pyrazolo[1,5-a]pyridine Derivatives: Potent and Orally Active Antagonists of Corticotropin-Releasing Factor 1 Receptor

  摘要：

  Design, synthesis, and structure activity relationships of a series of 3-dialkylamino-7-phenyl pyrazolo[1,5-a]pyridines (I) as selective antagonists of the corticotropin-releasing factor 1 (CRF1) receptor are described. The most prominent compound to emerge from this work, 46 (E2508), exhibits potent in vitro activity, excellent drug-like properties, and robust oral efficacy in animal models of stress-related disorders. It has advanced into clinical trials.

  DOI：

  10.1021/jm300259r

文献信息

• Synthesis and Structure–Activity Relationships of Pyrazolo[1,5-<i>a</i>]pyridine Derivatives: Potent and Orally Active Antagonists of Corticotropin-Releasing Factor 1 Receptor
  作者：Yoshinori Takahashi、Shigeki Hibi、Yorihisa Hoshino、Koichi Kikuchi、Kogyoku Shin、Kaoru Murata-Tai、Masae Fujisawa、Mitsuhiro Ino、Hisashi Shibata、Masahiro Yonaga

  DOI：10.1021/jm300259r

  日期：2012.6.14

  Design, synthesis, and structure activity relationships of a series of 3-dialkylamino-7-phenyl pyrazolo[1,5-a]pyridines (I) as selective antagonists of the corticotropin-releasing factor 1 (CRF1) receptor are described. The most prominent compound to emerge from this work, 46 (E2508), exhibits potent in vitro activity, excellent drug-like properties, and robust oral efficacy in animal models of stress-related disorders. It has advanced into clinical trials.